Close Menu
    Facebook X (Twitter) Instagram
    SciTechDaily
    • Biology
    • Chemistry
    • Earth
    • Health
    • Physics
    • Science
    • Space
    • Technology
    Facebook X (Twitter) Pinterest YouTube RSS
    SciTechDaily
    Home»Health»A Major Drug Breakthrough Could Change How Ozempic and Wegovy Work
    Health

    A Major Drug Breakthrough Could Change How Ozempic and Wegovy Work

    By Duke UniversityOctober 23, 2026No Comments5 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn WhatsApp Email Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email Reddit
    Illustration of β Arrestin Modulation of GPCR Signaling
    Illustration of small molecule modulation of β-arrestins and GPCR signaling pathways based on concepts developed by the Lefkowitz Laboratory, Duke University. Credit: Ella Maru Studio / Duke University

    New compounds have overcome a longstanding challenge by directly targeting β-arrestins, proteins that regulate cellular signals, providing laboratory tools that could help guide more precise treatments with fewer side effects.

    A drug can hit its intended target and still have its effects cut short. That’s because cells have built-in molecular brakes that dial down signals after a receptor is activated. Now, scientists have discovered a way to interfere with those brakes, keeping an important signaling pathway active longer at the same receptor targeted by the blockbuster weight-loss drugs Ozempic and Wegovy.

    The breakthrough involves three new drug-like molecules that block β-arrestins, proteins that normally dampen cellular signals. In laboratory experiments, the compounds prolonged signaling without directly targeting the GLP-1 receptor, opening a potential path toward more precise medicines with fewer side effects.

    Decades ago, Duke University biochemist and cardiologist Robert J. Lefkowitz, MD, and his colleagues discovered those regulatory proteins, called β-arrestins. Now, work from his laboratory, published in Nature, gives scientists their first chemical tools for directly controlling β-arrestins and investigating how they shape cellular responses.

    β-Arrestins restrain some signals and trigger others

    β-Arrestins help regulate G protein-coupled receptors, or GPCRs, the family that includes the GLP-1 receptor. Nearly every human cell depends on GPCRs to receive and send signals for normal function, and roughly one-third of all FDA-approved drugs target them. When these receptors become active, G proteins relay their signals within the cell. β-Arrestins can limit the response by attaching to the receptors, dampening their signaling, and drawing them inside the cell.

    In the early 2000s, the Lefkowitz lab established that β-arrestins also initiate signaling pathways of their own. That discovery revealed two distinct roles for the proteins, restraining signals carried by G proteins while setting other cellular responses in motion. The new compounds let researchers interfere directly with both β-arrestin functions while preserving G protein signaling.

    Blocking β-arrestins preserves G protein signaling

    Finding and understanding these molecules took more than a decade of work by co-first authors Alem W. Kahsai, PhD, an assistant professor of medicine, and Natalia Pakharukova, PhD, a postdoctoral researcher. Lefkowitz said Kahsai “lived and breathed” the molecules 24 hours a day, bringing together collaborators from Duke and across the country to “describe an extraordinary amount of their biology.”

    The search started with a broad, unbiased screen of the National Cancer Institute’s extensive compound library. Researchers looked for molecules that might bind β-arrestins, then used additional tests to establish which candidates physically attached to the protein and stabilized it.

    Robert Lefkowitz, Alem Kahsai, and Natalia Pakharukova
    Robert Lefkowitz, MD, Alem Kahsai, PhD, and Natalia Pakharukova, PhD. Credit: Duke University

    To see what that binding accomplished, the team tested promising compounds in engineered human cells that allowed GPCR signaling to be monitored as it happened. Experiments then moved into physiologically relevant immune cells and heart muscle cells, allowing the researchers to assess whether the effects held beyond simplified laboratory systems.

    Three compounds emerged that prevented β-arrestins from being recruited to receptors. They blocked desensitization, which reduces a receptor’s responsiveness, and internalization, which moves receptors inside the cell. The compounds also suppressed β-arrestin-specific signaling. Tests across several GPCRs showed that G protein signaling remained intact, including at the GLP-1 receptor, where it continued longer than usual even during stimulation with Ozempic and Wegovy.

    “We tested these compounds from every angle we could think of before we were convinced they were bona fide β-arrestin inhibitors,” Kahsai said.

    Binding to a pocket reshapes β-arrestin

    Pakharukova uncovered a structural explanation using cryo-electron microscopy. She visualized a compound called Cmpd-5 nestled in a previously unknown pocket on β-arrestin. Binding there altered the protein’s overall shape, leaving it unable to fully engage with GPCRs. This mechanism is called allosteric inhibition, because a molecule binding at one site changes how the protein functions elsewhere.

    “Alem could have published a creditable paper about these molecules 10 years ago,” said Lefkowitz, Duke Health Distinguished Professor of Medicine and the study’s senior author. “But he’s a perfectionist. He wanted to figure out how they actually work.”

    The ability to control β-arrestins with pharmacological precision could help researchers determine how individual signaling pathways influence metabolism, immune responses, cardiovascular function, and brain signaling. Eventually, adjusting those pathways could offer a route to more precise treatments with fewer unwanted side effects.

    Reference: “Small-molecule modulation of β-arrestins” by Alem W. Kahsai, Natalia Pakharukova, Henry Y. Kwon, Kunal S. Shah, Caroline T. del Real, Bowie N. Shreiber, Jason G. Liang-Lin, Paul J. Shim, Mason A. Lee, Van A. Ngo, Allison M. Schwalb, Uyen Pham, Anand Chundi, Haoran Jiang, Emmanuel Flores-Espinoza, Samuel Liu, Preston C. Nibley, Dana K. Bassford, Hyunggu Hahn, Cal A. Kunzle, Brittany N. Thomas, Jihee Kim, Yang Zhou, Jialu Wang, Xingdong Zhang, Jeffrey S. Smith, Lindsay A. M. Rein, Alex R. B. Thomsen, Sudha K. Shenoy, Sudarshan Rajagopal, Lei Shi, Seungkirl Ahn, Howard A. Rockman, Ali Masoudi and Robert J. Lefkowitz, 24 June 2026, Nature.
    DOI: 10.1038/s41586-026-10683-5

    Funding: Howard Hughes Medical Institute, the National Institutes of Health, the St. Jude Children’s Research Hospital Collaborative Research Consortium on GPCRs, and the Mandel Foundation.

    Never miss a breakthrough: Join the SciTechDaily newsletter.
    Follow us on Google and Google News.

    Cell Biology Chemical Biology Duke University Pharmacology Popular Protein
    Share. Facebook Twitter Pinterest LinkedIn Email Reddit

    Related Articles

    Scientists Crack Cancer’s Hidden Defense With a Breakthrough Protein Discovery

    Surprising Finding: Scientists Discover New, Unexpected Mechanism of Cancer Cell Spread

    Scientists Discover Exactly How COVID-19 Wreaks Havoc on Human Lungs

    How Dietary Fat Affects Stem Cell Differentiation

    New Research Shows Cellular Clean-Up Can Also Sweep Away Forms of Cancer

    Lysosomes May Contribute to Alzheimer’s Disease

    Biomedical Engineers Grow Self-Healing Muscle

    Stressed VWF Proteins Can Cause Blood Clots

    Researchers Identify BAD as Key Seizure-Suppressing Protein

    Leave A Reply Cancel Reply

    • Facebook
    • Twitter
    • Pinterest
    • YouTube

    Don't Miss a Discovery

    Subscribe for the Latest in Science & Tech!

    Trending News

    Researchers Find That Arthritis May Leave a Hidden Memory in Your Joints

    Scientists Discover a Hidden Cholesterol Switch That Could Change How We Treat Heart Disease

    A Major Drug Breakthrough Could Change How Ozempic and Wegovy Work

    A Cave Full of Ancient Human Remains Has a Strange Secret: Where Are All the Males?

    MIT Scientists Reprogram Immune Cells Inside the Body To Destroy Cancer

    Scientists Discover a Hidden Oxygen Source Deep Inside Earth That Could Rewrite Our Planet’s History

    What if Dark Energy Was Once Negative? Scientists Uncover a Surprising New Possibility

    Scientists Discover a $10 Flood Protection Trick That Works Better Than Sandbags

    Follow SciTechDaily
    • Facebook
    • Twitter
    • YouTube
    • Pinterest
    • Newsletter
    • RSS
    SciTech News
    • Biology News
    • Chemistry News
    • Earth News
    • Health News
    • Physics News
    • Science News
    • Space News
    • Technology News
    Recent Posts
    • A Bizarre 170-Million-Year-Old Predator Is Rewriting What We Know About Ancient Crocodiles
    • Medieval Children Were Exposed to Shocking Levels of Lead, 1,000 Years Before the Industrial Revolution
    • Eating 30% Less Food Has an Unexpected Effect on DNA, Study Finds
    • Tiny Atomic Defects Reveal a Quantum Secret Hidden Inside an Unusual Metal
    • Scientists Develop a Clever New Way To Kill Cancer Cells From the Inside
    Copyright © 1998 - 2026 SciTechDaily. All Rights Reserved.
    • Science News
    • About
    • Contact
    • Editorial Board
    • Privacy Policy
    • Terms of Use

    Type above and press Enter to search. Press Esc to cancel.